

# Anti-HLA-DR Reference Antibody (IMMU-114)

Recombinant Antibody

Catalog # APR10534

## Product Information

---

<b>Application</b>	FC, Kinetics, Animal Model
<b>Primary Accession</b>	<a href="#">P01903</a>
<b>Reactivity</b>	Human
<b>Clonality</b>	Monoclonal
<b>Isotype</b>	IgG4SP
<b>Calculated MW</b>	28621

## Additional Information

---

<b>Target/Specificity</b>	HLA-DR
<b>Endotoxin</b>	
<b>Conjugation</b>	Unconjugated
<b>Expression system</b>	CHO Cell
<b>Format</b>	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

## Protein Information

---

<b>Name</b>	HLA-DRA
<b>Synonyms</b>	HLA-DRA1
<b>Function</b>	<p>An alpha chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the beta chain HLA- DRB, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DR-restricted CD4-positive T cells. This guides antigen-specific T- helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells (PubMed:<a href="#">15265931</a>, PubMed:<a href="#">15322540</a>, PubMed:<a href="#">17334368</a>, PubMed:<a href="#">22327072</a>, PubMed:<a href="#">24190431</a>, PubMed:<a href="#">27591323</a>, PubMed:<a href="#">29884618</a>, PubMed:<a href="#">31495665</a>, PubMed:<a href="#">8145819</a>, PubMed:<a href="#">9075930</a>). Typically presents extracellular peptide antigens of 10 to 30 amino acids that arise from proteolysis of endocytosed antigens in lysosomes (PubMed:<a href="#">8145819</a>). In the tumor microenvironment, presents antigenic peptides that are primarily generated in tumor-resident APCs likely via phagocytosis of apoptotic tumor cells or macropinocytosis of secreted tumor proteins (PubMed:<a href="#">31495665</a>). Presents peptides derived from intracellular proteins that are trapped in autolysosomes after macroautophagy, a</p>

mechanism especially relevant for T cell selection in the thymus and central immune tolerance (PubMed:[17182262](#), PubMed:[23783831](#)). The selection of the immunodominant epitopes follows two processing modes: 'bind first, cut/trim later' for pathogen-derived antigenic peptides and 'cut first, bind later' for autoantigens/self- peptides (PubMed:[25413013](#)). The anchor residue at position 1 of the peptide N-terminus, usually a large hydrophobic residue, is essential for high affinity interaction with MHCII molecules (PubMed:[8145819](#)).


## Cellular Location

Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass type I membrane protein. Early endosome membrane; Single-pass type I membrane protein. Late endosome membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Autolysosome membrane; Single-pass type I membrane protein. Note=The MHCII complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation (PubMed:18305173, PubMed:9075930). Component of immunological synapses at the interface between T cell and APC (PubMed:15322540, PubMed:29884618).


## Tissue Location

Expressed in professional APCs: macrophages, dendritic cells and B cells (at protein level) (PubMed:15322540, PubMed:23783831, PubMed:31495665). Expressed in thymic epithelial cells (at protein level) (PubMed:23783831).

## Images



Anti-HLA-DR Reference Antibody (IMMU-114) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-HLA-DR Reference Antibody (IMMU-114) is more than 98.76% ,determined by SEC-HPLC.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.